Skip to main content
. 2019 Mar 15;17(6):4891–4900. doi: 10.3892/ol.2019.10153

Figure 2.

Figure 2.

Figure 2.

Progression-free survival according to the treatment arm for (A) E-cadherin expression <8 and (B) E-cadherin ≥8. EB, erlotinib/bevacizumab; PGB, cisplatin/gemcitabine/bevacizumab.